Prudential Jennison Health Sciences Fund (PHLAX)

44.50
Net Asset Value
-1.53%
1 Day
-0.69%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.81%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector- such as pharmaceutical companies- biotechnology companies- medical device manufacturers- healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets- revenues or profits from operations in the healthcare sector. The fund is non-diversified.

Performance

1 month-1.11% 3 years-0.57%
3 months-8.77% 5 years+14.07%
1 year+13.62% Since inception+14.50%
Data through --

Peer Comparisonvs. Health

 PHLAXCategory
Performance 5-yr return+14.07%+14.29%
Expense ratio1.81%1.30%
Risk 5 year sharpe ratio0.780.92
Net assets$2.2B$3.0B
Average market cap$11.7B$10.0B
Average P/E--22.2
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyPrudential Funds (PGIM Investments)
Fund manager & tenureDavid Chan / 18 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock94.73%
International stock3.77%
Fixed income1.35%
Other0.16%
Cash0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 97.95%
Consumer service 1.34%
Business service 0.00%
Consumer goods 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth6.47%
BMRN Biomarin Pharmaceutical Inc5.32%
HUM Humana Inc4.09%
SAGE SAGE Therapeutics Inc3.96%
ILMN Illumina Inc3.54%
ASMB Assembly Biosciences Inc3.47%
BMY Bristol-Myers Squibb3.41%
AGN Allergan3.27%
SRPT Sarepta Therapeutics Inc2.96%
BLUE bluebird bio Inc2.82%